Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCLA-129 in Advanced NSCLC
NCT06885840Phase 2Not yet recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pamvatamig in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
pamvatamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06885840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885840.